アベルマブ (Japanese Wikipedia)
Analysis of information sources in references of the Wikipedia article "アベルマブ" in Japanese language version.
refsWebsite
Global rank
Japanese rank
low place
4,972nd place
6,690th place
394th place
low place
low place
low place
low place
biopharmadive.com
- “Pfizer, Merck KGaA fourth to market with PD-1/L1 inhibitor” (英語). BioPharma Dive. 2021年10月9日閲覧。
doi.org
- “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. The New England Journal of Medicine 369 (2): 134–44. (July 2013). doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.
- “Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial”. Journal for Immunotherapy of Cancer 6 (1): 7. (January 2018). doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.
drugs.com
- “Avelumab (Bavencio) Use During Pregnancy”. Drugs.com (29 May 2019). 2 August 2020閲覧。
- “Bavencio Monograph for Professionals”. Drugs.com. American Society of Health-System Pharmacists, Inc. (27 January 2020). 2 August 2020閲覧。
europa.eu
ema.europa.eu
- “Public summary of opinion on orphan designation: Avelumab for the treatment of gastric cancer”. European Medicines Agency (9 January 2017). 2021年10月8日閲覧。
- “Bavencio: EPAR - Product Information”. European Medicines Agency (2017年9月18日). 2021年10月8日閲覧。
fda.gov
- "FDA approves first treatment for rare form of skin cancer". U.S. Food and Drug Administration (FDA) (Press release). 23 March 2017. 2020年8月2日閲覧。
この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。 - “FDA approves avelumab for urothelial carcinoma maintenance treatment”. U.S. Food and Drug Administration (FDA) (30 June 2020). 2 August 2020閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
- “FDA grants accelerated approval to avelumab for urothelial carcinoma”. U.S. Food and Drug Administration (9 May 2017). 30 September 2020閲覧。 この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
- “FDA approves avelumab plus axitinib for renal cell carcinoma”. U.S. Food and Drug Administration (FDA) (14 May 2019). 29 September 2020閲覧。
- “FDA approves avelumab for urothelial carcinoma maintenance treatment”. U.S. Food and Drug Administration (FDA) (30 June 2020). 29 September 2020閲覧。
genome.jp
- “KEGG DRUG: アベルマブ”. www.genome.jp. 2021年10月8日閲覧。
nih.gov
ncbi.nlm.nih.gov
- “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. The New England Journal of Medicine 369 (2): 134–44. (July 2013). doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.
- “Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial”. Journal for Immunotherapy of Cancer 6 (1): 7. (January 2018). doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.
pmc.ncbi.nlm.nih.gov
- “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. The New England Journal of Medicine 369 (2): 134–44. (July 2013). doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.
- “Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial”. Journal for Immunotherapy of Cancer 6 (1): 7. (January 2018). doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.
pubmed.ncbi.nlm.nih.gov
- “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. The New England Journal of Medicine 369 (2): 134–44. (July 2013). doi:10.1056/NEJMoa1305133. PMC 4126516. PMID 23724846.
- “Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial”. Journal for Immunotherapy of Cancer 6 (1): 7. (January 2018). doi:10.1186/s40425-017-0310-x. PMC 5774167. PMID 29347993.
dailymed.nlm.nih.gov
- “Bavencio- avelumab injection, solution, concentrate”. DailyMed (2 July 2020). 2 August 2020閲覧。
pfizer.co.jp
- “本邦初の抗PD-L1抗体薬「バベンチオ(R)」製造販売承認を取得～メルケル細胞がんに対する本邦初かつ唯一の治療薬～”. www.pfizer.co.jp. 2021年10月8日閲覧。
- “抗PD-L1抗体バベンチオ(R)（一般名：アベルマブ（遺伝子組換え））、インライタ(R)（一般名：アキシチニブ）との併用療法で追加適応症の承認取得～進行腎細胞がんのファーストライン治療に新たな選択肢～”. www.pfizer.co.jp. 2021年10月8日閲覧。
- “抗PD-L1抗体バベンチオ(R)（一般名：アベルマブ（遺伝子組換え））、局所進行または転移性の尿路上皮がんの適応症追加の承認取得”. www.pfizer.co.jp. 2021年10月8日閲覧。
pfizer.com
- “Merck-Pfizer Alliance Avelumab Fact Sheet”. 2 December 2015閲覧。